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While several randomized controlled trials have shown that continuous positive airway pressure (CPAP) reduces sleepiness, residual sleepiness still occurs in up to 13% of patients adequately treated with CPAP. 2 According to a large multicenter French registry, the prevalence of residual sleepiness in OSA with CPAP use > 3 h/night was 13%, and > 6 h/night was 9%. At the time of diagnosis, patients with residual sleepiness had worse subjective appreciation of their health, felt more fatigued, and complained more frequently of CPAP side effects. 3 The mechanism of residual sleepiness despite adequate treatment of OSA remains unknown. One proposed mechanism is that these patients are more susceptible to intermittent hypoxia than patients that are not sleepy and suffer injury to specifi c neuronal systems that promote wakefulness. 4 Currently, modafi nil and armodafi nil (the longer lasting Renantiomer of racemic modafi nil) are the only wakefulness promoting agents (WPA) approved as adjuvant pharmacotherapy for residual sleepiness in OSA. Their mechanism of action is uncertain, but it is postulated that they modulate glutamate, gamma-aminobutyric acid, histamine, hypocretin, and monoamines in a complex neuronal network which arises in the midbrain reticular formation and innervates the hypothalamus, thalamus, and basal forebrain. 5 They are better tolerated and are less addictive than other CNS stimulants. They have been successfully used to reduce sleepiness in patients with narcolepsy and idiopathic hypersomnia. 6 This success evoked interest for testing them in treating residual sleepiness in patients with OSA. The effects of WPAs on residual sleepiness in patients with OSA has been studied in a variety of settings and led to the approval by the United States Food and Drug Administration in 2007. 7 On the other hand, the European Medicines Agency has restricted the use of modafi nil to narcolepsy because the evidence for use in patients with OSA was deemed weak and because of concerns about serious side effects. 8 In this review, we aimed to conduct a meta-analysis to evaluate the effect of wakefulness promoting agents (armodafi nil and modafi nil) in patients with OSA.
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METHODS
Data Sources
Using relevant keywords, MeSH terms, and text, we performed a systematic search of MEDLINE (1966 to September 2014) via Ovid, EMBASE (1980 to September 2014) via Scopus, and the Cochrane Central Register of Controlled Trials (see Appendix). We also examined bibliography of included articles to identify additional references.
Study Selection
We considered only double-blind, randomized placebo-controlled trials (RCTs) that compared modafinil or armodafinil to placebo, in adults who met established criteria for the diagnosis of OSA, adequate CPAP use, and who complained of residual sleepiness. Open label extension studies, secondary analyses on existing placebo controlled RCTs, patient populations with comorbid psychiatric conditions (other than depression) were excluded. Studies done with less than 30 patients, animal studies, review articles, case reports, and abstracts in languages other than English were also excluded from analysis.
Primary outcomes of interest were the Epworth Sleepiness Scale (ESS) and the mean sleep latency times on the maintenance of wakefulness test (MWT). Secondary outcomes included the Clinical Global Impression of Change (CGI-C), impact of WPAs on CPAP usage, and the frequency of common adverse effects.
Data Extraction and Synthesis
Two authors independently reviewed titles and abstracts of the identified resources. They obtained the full text of all studies of possible relevance for independent assessment. All the authors decided which trials fit the inclusion criteria. The authors resolved any disagreement by consensus. Two authors performed data extraction independently with specific data extraction forms, and the third confirmed the accuracy. Outcome variables and 95% confidence intervals (CI) were derived from each study and summary statistics were applied as appropriate. In cases where these were not reported in the abstract or full text, we extracted them from the figures using Plot Digitizer 2.6.3 software.
Statistical Analysis
A weighted treatment effect was calculated across trials. For continuous variables, the results were expressed as weighted mean differences with 95% CI using inverse variance method. For dichotomous variables, the results were expressed as risk difference and relative risk (RR) with 95% CIs using inverse variance method. Shared placebo group encountered in one study was split equally between two intervention arms. Statistical heterogeneity was identified and measured by the Q and I 2 statistic. We used a p value (< 0.01) based on the Q statistic or I 2 magnitude ≥ 50% to define significant heterogeneity. Fixed effects model was used for all analysis. Methods based on random effects model were chosen when significant heterogeneity were present. All statistical analysis was done using RevMan 5.3 software.
Assessment of Risk of Bias
Two authors independently assessed risk of bias in the included studies with specific focus on random sequence generation and treatment allocation concealment. Risk of bias was rated "low" if method of random sequence generation was described, "high" if non-random methods were used for selection, and "unclear" if it was not described. Similarly, we rated risk of performance bias as "low," "high," or "unclear," depending on whether appropriate methods to conceal treatment allocation were described. We also assessed the adequacy of blinding of participants, personnel, and outcome assessors. Disagreements were resolved by consensus.
RESULTS
Study Selection
Out of 118 abstracts screened and 12 full text articles reviewed, we included 6 studies 9-14 with a total of 1,479 participants, in our final meta-analysis (Figure 1) . We excluded open label extension studies, and studies in which secondary analysis was done on an existing data set to avoid duplication of patients. All RCTs excluded patients with psychiatric comorbidities except Krystal et al. 13 They specifically studied patients with treated comorbid depression. All studies were performed in Europe and North America except the study by Inoue et al.
14 which was performed in Japan.
Study Characteristics
All study participants were adults (age > 18) who had OSA with residual sleepiness and were on stable and effective CPAP therapy. The characteristics of included studies ( Table 1) , criteria for defining OSA, residual sleepiness, and effective CPAP therapy ( Table 2) were similar between all trials. Dosage regimens for modafinil and for armodafinil differed between the trials with the presumed objective of minimizing side effects during the titration to a maximum effective dose.
Study Quality
Risk of bias was rated unclear in one or more key domains in four of these studies (Figure 2) . Pack et al. 9 did not mention the method of random allocation. For Black et al., 10 it was unclear if participants and personnel could guess the allocation based on dosage regimen of the study drug. Hirshkowitz et al. 12 did not mention if outcome assessment was blinded. For Krystal et al., 13 initial outcome visit was not blinded, and it is not mentioned if placebo dose was also titrated to mimic armodafinil dose titration in the study group. 
Outcomes
Primary Outcomes
Epworth SlEEpinESS ScalE (ESS)
This outcome was studied and reported by all 6 RCTs. The mean difference was 2.51 points (95% CI, 2.00-3.02), in favor of WPAs (Figure 3) . There was no significant heterogeneity (I 2 = 26%, p value of Q statistic 0.23). Data for this outcome was derived from graphs for Pack et al. 9 and Hirshkowitz et al. 12 MEan SlEEp latEncy tiME in MaintEnancE of wakEfulnESS tESt (Mwt) This outcome was studied and reported by 5 RCTs. The mean difference was 2.87 minutes (95% CI, 1.86-3.88) in favor of WPAs (Figure 4) . There was no significant heterogeneity (I 2 = 0%, p value of Q statistic 0.61).
Secondary Outcomes clinical Global iMprESSion of chanGE (cGi-c)
This outcome was studied and reported by 5 RCTs. Use of WPAs increased the reporting of minimal improvement on the CGI-C by 26% (RR 1.56; 95% CI, 1.59-1.86) (Figure 5) . There was significant heterogeneity across studies (I 2 = 53%, p value of Q statistic 0.06) and random effects model was used.
MEan chanGE in duration of cpap uSE
This outcome was reported by 3 RCTs ( Table 3) . Use of CPAP decreased more in the WPA arms than in the control arms by a weighted mean difference of 0.12 h (95% CI, 0.00-0.24, p = 0.05) (Figure 6 ). There was no significant heterogeneity (I 2 = 14%, p value of Q statistic 0.32).
Adverse Effects
The most common side effects reported were headaches, nausea, and dizziness ( Table 4) . Use of WPAs increased the risk of headaches by 8% (RR 1.98; 95% CI, 1.48-2.63) (Figure 7) . On subgroup analysis, armodafinil was associated with a lower rate of headache than modafinil (p < 0.05).
DISCUSSION
Our meta-analysis suggests that for patients with residual sleepiness despite adequate CPAP, treatment with modafinil or armodafinil reduced sleepiness and improved global impression of illness severity and response to therapy. The use of WPAs was associated with more headaches and a trend toward reduction in the use of CPAP.
The statement by the American Thoracic Society on sleep apnea and driving risk recommends against prescribing (1) and (2) in the figure. The shared placebo group was split equally between the two arms for the meta-analysis of continuous variables. WPA, wakefulness promoting agent.
stimulants because there is limited evidence that they reduce accidents and because of the concern that they might improve subjective measures of wakefulness more than objective ones, leading drivers to be overconfident despite their impairment.
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The American Academy of Sleep Medicine recommends using WPAs to treat residual sleepiness despite effective CPAP treatment when no other causes for sleepiness are identified, 16 while the American College of Physicians 17 and the British Thoracic Society 18 do not endorse their use. The European Medicines Agency restricts the use of modafinil to narcolepsy because it considers the evidence weak for indications other than narcolepsy and because of concerns for serious skin reactions (erythema multiforme, Steven-Johnsons syndrome, toxic epidermal necrolysis), suicidal ideation, and hallucinations. 8 From the date of initial marketing on December 1998 until January 2007, the United States Food and Drug Administration received reports of six cases of such serious skin reactions prompting a product labeling update. 19 Data on occurrence of such severe skin reactions was not reported in the trials included in this meta-analysis. Headaches, nausea, and dizziness were the most common side effects reported.
The pooled estimate for number needed to harm (NNH) for headache was 12, based on a pooled risk difference 0.08 (95% CI: 0.05 to 0.12). The number needed to treat (NNT) for the percentage of patients reporting at least a minimal improvement in CGI-C was 4, based on a pooled risk difference 0.26 (95% CI: 0.19 to 0.33). Therefore, the NNT-to-NNH ratio favors the use of WPAs, with the caveat that the pooled NNT derived from meta-analysis can be misleading given the variation in baseline risk and event rates across trials. 20 There were certain limitations of this meta-analysis. First, outcome measures such as polysomnographic parameters, functional outcome questionnaires, and cognitive outcomes, were included in some of the RCTs, but were not analyzed by us because they were not uniformly studied or reported. In addition, some RCTs did not report confidence intervals or standard errors of the mean in the article and we had to derive them from graphical data, which may be a source of error.
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Second, the RCTs were limited to 4 to 12 weeks of follow up, therefore we cannot comment on long term effects of using these agents. Third, we have combined analysis for armodafinil (1) and (2) indicates subgroup analysis of the 200 mg and 400 mg modafinil dosage arms respectively. WPA, wakefulness promoting agent. and modafinil and cannot determine if one is preferable to the other, although it appears that armodafinil had a lower incidence of headache. Additionally, dosage regimens across various RCTs were different and it was difficult to determine an optimal dosing strategy based on the available data. Fourth, there was one study which included patients with treated depression, which is an important confounding factor. Fifth, we were unable to determine the proportion of patients discontinuing the drugs from serious adverse events that were of concern to the European Medicines Agency.
We must mention that all trials included in this analysis received funding in part or whole from drug manufacturers which may be a source of bias. Industry-sponsored drug and device studies are more favorable to the sponsored product when compared to non-industry-sponsored studies and this bias cannot be measured by standard risk of bias assessment tools.
Since there is a dose-response relationship between CPAP and cognitive function, 23 physicians should pay close attention to CPAP use. In the trials included in this analysis, the average daily CPAP use was 6.5 hours. Therefore when a patient uses CPAP for 4-6 hours, the physician should first determine if residual sleepiness is due to short sleep time or because CPAP use is shorter than sleep time and then address each situation accordingly. On the other hand, patients that remain sleepy despite using CPAP for ≥ 6.5 hours are unlikely to increase their use of CPAP and are also unlikely to notice any improvement in their sleepiness. This group might benefit most from using WPAs.
In our practice, we prescribe modafinil to carefully selected patients with whom we discuss the potential risks and benefits of such treatment. Generally these are patients in whom sleepiness interferes significantly with study or work. Our approach begins by ruling out residual OSA, periodic limb movement disorder, depression, and drug-induced sleepiness. We then attempt to maximize CPAP use. We assess the relationship between total sleep time and CPAP use aiming to increase total sleep time and to eliminate any sleep without CPAP. If a patient continues to be sleepy after maximizing sleep time and CPAP use, we prescribe a trial of modafinil. We measure sleepiness before and after treatment with ESS and MWT and continue to treat if the response is satisfactory.
The modest decrease in CPAP use after treatment with WPAs, does not appear to be clinically relevant in the setting of these trials. Yet this trend might be more significant in clinical practice with wider use of these agents for longer periods combined with suboptimal monitoring of CPAP use. In addition, the effect of reduced CPAP on wakefulness might be masked by these agents. Therefore, physicians must monitor objectively and closely adherence with CPAP because it remains the treatment of OSA associated with less cardiovascular deathsan effect that has not been demonstrated for WPAs
This meta-analysis shows that, with a favorable NNT/NNH ratio, modafinil and armodafinil reduced sleepiness in patients that remained sleepy after adequate use of CPAP. Nevertheless, considering the source of funding of these trials, the concerns about serious adverse effects, and the trend for lesser CPAP use on treatment, we call on independent investigators to conduct longer and larger trials that address these issue as well as the appropriate methods for selecting patients and for monitoring them long-term.
ABBREVIATIONS
CGI-C, Clinical Global Impression of Change CI, confidence interval CPAP, continuous positive airway pressure ESS, Epworth Sleepiness Scale MSLT, multiple sleep latency test MWT, maintenance of wakefulness test NNH, number needed to harm NNT, number needed to treat OSA, obstructive sleep apnea PRISMA, Preferred Reporting Items for Systematic
Reviews and Meta-Analyses RCT, randomized controlled trial SD, standard deviation SEM, standard error of mean USFDA, United States Food and Drug Administration WPA, wakefulness promoting agent
